HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, and is an attractive target for new anti-HIV drugs. Its main function is to insert the viral DNA into the host chromosomal DNA, a step that is essential for its replication. However there are six different Protein Data Bank (PDB) entries of the same protein with the same amino acids with PDB IDs 1BIS, 1BIU, 1BIZ, 1HYV, 1HYZ and 1QS4. The present work focuses on the structure analysis of chain A of the different PDB entries of the same protein using in silico approaches via the Swiss Model structure assessment server, ANOLEA Assessment server and Ramachandran plot analysis. The structure assessment analysis reveals that there is a major difference among these PDB entries based on the energy assessment and structural analysis. The PDB ID 1BIU chain A is found to be the most stable and reliable structure for assisting computer aided drug designing.
INTRODUCTION
The integration of viral DNA into the host chromosome is a necessary process in the HIV replication cycle (Brown, 2000) . The key steps of DNA integration are carried out by the viral integrase protein, which is one of three enzymes encoded by HIV. Combination antiviral therapy with protease and reverse transcriptase inhibitors has demonstrated the potential therapeutic efficacy of antiviral therapy for the treatment of AIDS (Vandamme et al., 1998) . Integrase is an attractive target for antivirals because it is essential for HIV replication and unlike protease and reverse transcriptase, there are no known counterparts in the host cell. Furthermore, integrase uses a single active site to accommodate two different configurations of DNA substrates, which may constrain the ability of HIV to develop drug resistance to integrase inhibitors. Unlike protease and reverse transcriptase, for which several classes of inhibitors have been developed and co crystal structures have been determined, progress with the development of integrase inhibitors has been *Corresponding author. E-mail: salam10@tezu.ernet.in. Tel: +91-03712-267007 Ext 5432. Fax: +91-03712-267005. slow. A major obstacle has been the absence of good lead compounds that can serve as the starting point for the structure based inhibitor development. Although numerous compounds have been reported to inhibit integrase activity in vitro, most of these compounds exhibit little specificity for integrase and are not useful as lead compounds (Pommier et al., 1997) . HIV-1 integrase is a 32-kDa enzyme that carries out DNA integration in a two-step reaction (Brown, 2000) . Integrase is comprised of three structurally and functionally distinct domains and all three domains are required for each step of the integration reaction (Engelman et al., 1993) . The isolated domains form homodimers in solution and the threedimensional structure(s) of all three separate dimers have been determined (Dyda et al., 1994; Goldgur et al., 1998; Maignan et al., 1998; Lodi et al., 1995; Eijkelenboom et al., 1995; Cai et al., 1997) . Although little is known concerning the organization of these domains in the active complex with DNA substrates, integrase is likely to function as at least a tetramer (Dyda et al., 1994) . Extensive mutagenesis studies mapped the catalytic site to the core domain (residues 50-212), which contains the catalytic residues Asp-64, Asp-116, and Glu-152 (Engelman et al., 1992; Kulkosky et al., 1992) . The structure of this domain of HIV-1 integrase has been determined previously in several crystal forms (Dyda et al., 1994; Goldgur et al., 1998; Maignan et al., 1998) describes structures with bound magnesium and predicts that these structures would provide a more suitable platform for inhibitor binding than the earlier structure of the apoenzyme. The present study aims at the in silico structure assessment analysis of six different PDB entries of integrase protein of HIV in finding the best stable structure from these six different PDB entries for assisting computer aided drug designing. This in silico analysis will add up for designing a more reliable and accurate class of HIV inhibitors.
MATERIALS AND METHODS
The PDB ID of 1BIS, 1BIU, 1BIZ, 1HYV, 1HYZ and 1QS4 (Goldgur et al., 1998; Molteni et al., 2001; Goldgur et al., 1999) were retrieved from the Protein Data Bank (http://www.pdb.org/). Their three-dimensional structures are shown in Figure 1 . The threedimensional structures of chain A's of 1BIS, 1BIU, 1BIZ, 1HYV, 1HYZ and 1QS4 were analysed for structure assessment.
Initially the 3D structures of these proteins were assessed with Atomic Non-Local Environment Assessment (ANOLEA) a server that performs energy calculations on a protein chain, evaluating the "Non-Local Environment" (NLE) of each heavy atom in the molecule in which the energy of each pair wise interaction in the non-local environment is taken from a distance-dependent knowledge-based mean force potential that has been derived from a database of 147 non-redundant protein chains with a sequence identity below 25% and solved by X-Ray crystallography with a resolution lower than 3 Å (Melo and Feytmans, 1998).
Further the chain A's of the six three dimensional structures were accessed with PROCHECK (Laskowski et al., 1993) via the Swiss Model -Protein Structure and Model Assessment Tools (http://swissmodel.expasy.org/) for analyzing the Ramachandran plot (Ramachandran et al., 1963) and for visualizing the dihedral angles ψ against φ of the amino acid residues. Table 1 with ANOLEA energy assessment of chain A's of 1BIS, 1BIU, 1BIZ, 1HYV, 1HYZ, 1QS4 shows the total number of high energy amino acids of 1BIU with 13 high energy amino acids out of 147 amino acids and a total non-local energy of -1043 E/kt units. The table also shows 1BIZ with 18 high energy amino acids out of 147 amino acid residues with a total non-local energy of -889 E/kT units as the highest energy. This assessment shows that chain A of 1BIU is more stable in terms of low number of high energy amino acids (13/147 [8.84 %]), lowest total non-local energy (-1043 E/kT units) and lowest non-local normalized energy Z-score with -0.23 as compared to the chain A's of 1BIS, 1BIZ, 1HYV, 1HYZ and 1QS4.
RESULTS AND DISCUSSION
The ANOLEA energy assessment analysis of high energy amino acid residues of chain A of 1BIS, 1BIU, 1BIZ, 1HYV, 1HYV and 1QS4 is shown in Table 2 . In most of the cases the high energy amino acid was located between the CYS130 to ALA196. Chain A of 1BIU accounts an overall of 20.91 E/kT units of high energy amino acids as compared to 40.1 E/kT units of 1BIS chain A , 34.95 kT units of 1BIZ chain A, 33.64 E/kT units of both 1HYV and 1HYZ chain A and E/kT 55.88 units of 1QS4. The energy analysis of each high energy amino acid also revealed that each of the high energy residues of 1BIU chain A has a lower energy as compared to the other five chains which is shown in Figure 2 . The superimposition of the six chain A's of the PDB ID 1BIS, 1BIU, 1BIZ, 1HYV, 1HYZ, 1QS4 is shown in Figure 3 and it shows the region of the high energy amino acid region ranging from GLY189 to ALA196.
Further Ramachandran plot analysis reveals that 96.0% amino acid residues of chain A of 1BIS, 93.6% of Chain A 1BIU, 96.1% of Chain A of 1BIZ, 95.8% of Table 3 .
Conclusion
The chain A's of 1BIS, 1BIU, 1BIZ, 1HYV, 1HYZ and 1QS4 has been assessed for stability, energy analysis and geometrical errors using various assessment servers and programmes and found that the Chain A of 1BIU is more reliable and accurate as compared to chain A's of 1BIS, 1BIZ, 1HYV, 1HYZ and 1QS4. Chain A of 1BIU would be a promising structure for assisting computer aided drug designing in targeting HIV Integrase inhibitors.
